$CDNA

Baron group trims CareDx (CDNA) stake to 3.75% in latest 13G/A

CareDx, Inc. said it received an amended Schedule 13G/A from Baron Capital Group, Inc., BAMCO, Inc., Baron Capital Management, Inc., and Ronald Baron. The filing reports shared beneficial ownership of 1,937,326 CareDx common shares, or 3.75% of the class, down to 5% or less, with shared voting and dispositive power.

Original reporting
Published Aug 14, 2026, 2:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

For traders, the key new fact is the updated beneficial ownership percentage (3.75%) and the breakdown between BAMCO (3.22%) and Baron Capital Management (0.53%), confirming the position is now 5% or less.

02

Market read

This is a regulatory ownership update that may slightly affect sentiment around shareholder influence, but it does not provide new fundamentals or guidance.

03

What to watch

The filing describes shared voting and dispositive power and economic rights via advisory clients, so the practical control dynamics may differ from headline percentage alone.

Relevance 4/10Novelty 4/10Timing: today’s SEC 13G/A filing update

Background

The article summarizes an amended Schedule 13G/A filed by Baron Capital Group, BAMCO, Baron Capital Management, and Ronald Baron regarding their beneficial ownership of CareDx common stock.

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx disclosed in an amended Schedule 13G that Baron Capital Group and Ronald Baron reduced beneficial ownership to 3.75% (below 5%).

Expected impact

Likely limited near-term impact; any move would be sentiment-driven rather than a fundamental change.

Evidence & confidence

This is an SEC ownership disclosure with no stated intent to buy/sell beyond the reduced stake, and it does not include new operational or financial information.

Market effects

Minimal, as the disclosure is company-specific and does not indicate broader sector developments.

None indicated.

None indicated.

Counterpoint

The stake reduction could reflect portfolio rebalancing rather than a change in conviction, so the market may overreact to the 5% threshold crossing.

Key entities

  • CareDx, Inc.

    Subject of the Schedule 13G/A ownership disclosure summarized in the article.

  • Baron Capital Group, Inc.

    Reports beneficial ownership of 1,937,326 shares, 3.75% of the class, with shared voting and dispositive power.

  • BAMCO, Inc.

    Reports shared voting and dispositive power over 1,662,887 shares, about 3.22% of the class.

  • Baron Capital Management, Inc.

    Reports shared voting and dispositive power over 274,439 shares, about 0.53% of the class.

  • Ronald Baron

    Reports beneficial ownership of 1,937,326 shares, 3.75% of the class, with shared voting and dispositive power.

Related articles

$CDNAMedAI 8/10

CareDx Q2 Earnings Call Highlights

CareDx (NASDAQ:CDNA) provided Q2 earnings call guidance. Full-year testing volume is forecast at 258,000 to 266,000 tests and testing-services revenue around $400 million, including $24 million specialty oncology. Patient and digital revenue is expected at $72 million, lab products $23 million, and non-GAAP gross margin 71% to 73%. The company also discussed Medicare LCD coverage, Q3 and Q4 test assumptions, and pipeline updates for AlloHeme and HistoMap.

$CDNAHighAI 9/10

Why CareDx Stock Jumped Today

CareDx (CDNA) shares rose 14.72% after the company raised its full-year sales and earnings outlook. In Q2, revenue grew 52% to $132 million and adjusted net income rose to $20 million, or $0.37 per share. CareDx increased FY revenue guidance to $490M-$500M and EBITDA to $66M-$78M, citing demand and reimbursement coverage.

$CDNAHigh

CareDx, Inc. (CDNA): Results of Operations and Financial Condition

CareDx, Inc. (CDNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cdna-20260730_earningsrele.htm EX-99.1 Document Exhibit 99.1 CareDx Announces Second Quarter 2026 Financial Results Second Quarter Revenue Growth of 52% to $132 Million Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66